In this study, we tested the effects of targeting the PI3K pathway using the dual PI3K/mTOR inhibitor PI-103 with the intention of preventing the migration of two GBM cell lines differing in p53 and PTEN status [34] as well as in their invasive capacities [35]. Here, PTEN is linked to glioblastoma.